Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular DiseaseGlobeNewsWire • 10/31/23
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCTGlobeNewsWire • 10/25/23
Beam Therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026Market Watch • 10/19/23
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines PipelineGlobeNewsWire • 10/19/23
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?The Motley Fool • 10/03/23
This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.The Motley Fool • 09/08/23
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing MutationGlobeNewsWire • 09/07/23
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LLGlobeNewsWire • 09/05/23
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall StreetThe Motley Fool • 08/26/23